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ABSTRACT 
 
Atopic dermatitis (AD) may be worsened by stress and anxiety. Serotonin (5-
hydroxytryptamine; 5-HT) is an important mediator in stress and anxiety. 
   In the present thesis serotonergic mechanisms were studied in atopic dermatitis (AD). 
   In an atopic-like mouse model, NC/Nga, that was subjected to chronic mild stress, we 
studied expression of serotonergic markers 5-HT1A and 5-HT2A receptors (R) and 
serotonin transporter protein (SERT) in skin, cerebrum and cerebellum. There was an 
upregulation of 5-HT1AR in the skin, cerebrum and cerebellum, during inflammation, 
irrespective of stress, while the 5-HT2AR was upregulated in the cerebrum, 
hippocampal CA1 area, and in the cerebellum, Purkinje cell layer, while being 
downregulated in the skin, during chronic mild stress. 
   In human AD patients serotonergic markers in relation to extent of the disease, 
pruritus, chronic stress and psychodemographic data with focus on trait anxiety and 
depression, were studied. We found a correlation between the extent of the disease and 
dermal 5-HT1AR-positive dermal inflammatory cells in the lesional skin and 5-
HT2AR-positive vessels in the non-lesional skin, respectively. There was a correlation 
between depression with the epidermal positive 5-HT1AR fraction, while a reverse 
correlation with the number of 5-HT2AR expressing vessels, both in the lesional skin. 
In the lesional skin there was a reverse correlation for the basal SERT immunoreac-
tivity with stress susceptibility. 
   Moreover, the effect of intradermal injection of 5-HT was studied in patients with AD 
and in healthy controls, on vascular response and pruritus, estimated by a computerized 
VAS recorder. No difference was seen regarding pruritus, while the vascular response 
to 5-HT was reduced in the AD patients, compared to the healthy controls. 
   5-HT seems to have a role in AD.  
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1 INTRODUCTION 
 
1.1 ATOPIC DERMATITIS  
 
Atopic dermatitis (AD) is a chronic inflammatory highly pruritic disease, with a dry 
skin. AD usually occurs in people who have an atopic constitution. This means that 
they may develop any or all of three closely linked conditions; AD, hay fever (allergic 
rhinitis) and asthma.  
 
1.1.1 Epidemiology 
 
AD affects up to 15% of the Swedish population among children and around 2-3% of 
adults. AD most often begins in childhood before the age of five and may persist into 
adulthood. For some, it flares periodically and then subsides for a time, even up to 
several years.
1
 
   A female preponderance for AD has been reported,
1
 also dependent on age.
2
 The 
prevalence of the AD is increasing continuously. AD is considered as a major health 
problem worldwide, with a high prevalence in children in the USA, the Northern and 
Western Europe, urban Africa, Japan, Australia, and industrialized countries. 
Interestingly, the prevalence of AD is lower in agricultural countries such as China and 
in Eastern Europe, rural Africa, and central Asia.
1
 
 
1.1.2 Clinical features  
 
The diagnosis of AD may be made by using the Williams criteria.
3
 The clinical signs 
and symptoms of AD include itching and scratching, which may be severe, especially 
at night. The disease is also characterized by erythematous papules with excoriations 
and serous exudates in the acute phase and, in addition, lichenification in the chronic 
phase, and with a generally dry skin. Typical distribution in small children includes 
 2 
extensor side and face, while there is a predilection for flexures in older children and 
adults. In children and adults the disease may also affect the skin around the eyes, 
including the eyelids. In the adult phase there may also be a cranial localization as well 
as a localization to the hand area. 
 
1.1.3 Worsening factors 
AD can be worsened by several different factors such as climate, environmental factors, 
microbial agents and stress. AD is usually aggravated by a low humidity climate, high 
ambient temperatures and during dry cold weather. Among environmental factors, 
soaps, antiseptics, chlorine in swimming pools may worsen the disease. Bacterial 
infection like staphylococci and streptococci and/or yeasts like malassezia and candida, 
may play an important role in triggering AD.
1
 
   Finally adults and children with AD are usually experiencing an exacerbation in AD 
secondary to mental or social stress.  Thus, it has been earlier reported that AD is often 
worsened due to stress and anxiety 
4,5
 and a special personality of these patients, being 
more prone to anxiety, has been described.
6
 Patients with AD have been reported to 
have higher values for state and trait anxiety compared to healthy controls.
7
 While the 
extent of AD did not show a correlation with psychological parameters, pruritus 
correlated with state and trait anxiety.  
 
1.1.4 Pathogenesis  
 
The pathogenesis of AD is complicated.
8
 It is necessary to study the skin barrier 
dysfunction, itch sensation, abnormal immune responses, and incessant infection of 
Staphylococcus (S.) aureus to develop an effective treatment; however, the 
mechanisms have not yet been fully revealed.  
   3 
AD is a highly complex genetic disease with phenotype-specific genes likely playing 
a significant role along with atopy genes. Filaggrin (FLG) mutations have an 
important role for the skin barrier. FLGs are filament-associated proteins which bind to 
keratin fibres in the epidermal cells. Skin barrier defect is considered as one of the 
basic pathophysiologic abnormality of AD. Moreover, a dysfunctional skin barrier 
precedes the inflammation process, as well as the epidermal barrier defects initiate the 
development of AD. An intact skin barrier is an important first line of defense against 
various factors such as irritants, allergens and microbes.  
    It is well known that itch is the major symptom of AD, which impacts most 
considerably on the quality of life of patients. The limited effect of non-sedating anti-
histamine indicates that there are other mediators than histamine which might be 
involved, such as neuropeptides and cytokines. 
    There are several well-characterized cutaneous immune and systemic abnormalities 
in AD, including raised T helper (Th) 2-type cytokine expression in acute lesions, 
elevated serum immunoglobulin (Ig) E and sensitization to allergens, increased 
numbers of T cells expressing cutaneous lymphocyte-associated antigen (CLA), as 
well as decreased expression of anti-microbial peptides. In chronic lesions there is a 
Th1-type cytokine expression besides the Th2-type. Inappropriate adaptive immune 
response, with elevated IgE levels has been correlated with the severity of disease and 
infectious complications. Abnormalities in the body innate immune system, including 
diminished recruitment of cells such as neutrophils to the skin, reduction of the anti-
microbial peptides, and epidermal barrier defects may play an essential role in 
infection or microbial colonization in the skin of AD patients. 
   Patients with AD have a unique susceptibility to be infected or colonized by a 
number of microbial organisms, mainly S. aureus, which can be cultured from 90% of 
skin lesions and significantly can colonize normal appearing skin in AD.
8
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1.1.5  The atopic mouse 
There are limitations on studies using human AD subjects, and application of the 
experimental approach to patients is difficult. Therefore, analysis using laboratory 
animals is essential. There are several mouse models to study AD. 
9-10
 
    The probably most used animal model is the NC/Nga mouse, originated from Japan 
as a fancy mouse and established as an inbred strain.
11
 The NC/Nga spontaneously 
develop dermatitis, when kept in a non-sterile pathogen-free environment, but there is 
also a substrain in which dermatitis is  induced by topical application of a mite 
antigen
12
 or picryl chloride.
13
   
    NC/Nga mouse model manifests clinical and immunological aspects similar to AD 
patients-like skin manifestations, suggesting that this NC/Nga mouse model is an 
appropriate model for exploring the pathogenesis and treatment of human AD. The skin 
lesions of inbred NC/Nga mice are clinically and histologically very similar to human 
AD. Scratching behavior, the first sign of the skin changes, occurs at 6-8 weeks, and 
is followed by rapidly developing erythematous, erosive lesions with edema, and 
hemorrhages on the face, ears, neck, and back. The histological examination shows 
dermal infiltration with eosinophils and mononuclear cells before the appearance of 
clinical skin manifestations. Hyperparakeratosis, hyperplasia, and spongiosis are 
observed in the skin lesions at the age of 17 weeks.
10,14
 
 
1.2 NEUROCUTANEOUS INTERACTION  
There is a bilateral contact between the neuroendocrine system and the immune system, 
including the skin, to which the skin belongs.
5,15  
(Fig.1). 
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Fig. 1. Neuroendocrine system and skin response to psychological stress (Suarez et 
al.
16
 , with permission from the authors). 
 
That means that we may find ligands and ligand-receptors for neuromediators at central 
and peripheral locations. Stress involves an activation of the hypothalamic-pituitary-
adrenal (HPA) axis, autonomic nervous system, and also neuropeptides. 
   Different mediators are responsible for this contact between the neuroendocrine and 
skin, being activated during stress.
16
 One important mediator is 5-hydroxytryptamine 
(5-HT; serotonin). It has earlier been reported that acute stress is generally associated 
with an increase in the turnover of 5-HT, whereas chronic stress is usually associated 
with a sustained increase in the plasma cortisol, and causes a reduction in 5-HT 
turnover and release.
17
 
   There are important brain areas associated with stress, such as the prefrontal cortex, 
hippocampus and amygdale. In addition, profound changes in neuromediator 
expression, including serotonergic changes, in the cerebellum due to chronic stress, 
have been reported.
18
 Recent studies 
19-22  
have indicated a connection between chronic 
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inflammation and the cerebellum, adding to the complex interaction between the neuro-
endocrine and the immune systems. 
 
1.2.1 Neurocutaneous interaction in atopic dermatitis 
In AD lesions, there are numerous specific alterations in skin neurophysiology as well 
as skin neurobiology. It has been stated that the sensory functions of the skin are 
modified in AD patients.
20
 There are various neurotransmitters and neurohormones 
that are involved in AD pathophysiology. Approximately 30 of them have been 
described in human skin, e.g., hormones, neuropeptides and classical neurotrans-
mitters such as monoamines, acetylcholine, adrenocorticotropic hormone (ACTH), 5-
HT,  calcitonin gene-related peptide, angiotensin, corticotropin-releasing hormone 
(CRH), endorphins, enkephalins, galanin, histamine, gastrin-releasing hormone, 
melanocyte stimulating hormone (MSH),  nitric oxide (NO), neurokinin A and B, 
neuropeptide Y, neurotensin, peptide histidine isoleucine  (PHI), peptide histidine 
methionine (PHM), prolactin, parathyroid hormone, somatostatin, substance P, and 
vasoactive intestinal polypeptide (VIP).
20
  
   Itch is an important hallmark of symptoms of the AD disease. There is a variety of 
peripheral and central mediators suggested to play a role in the pathophysiology 
of this itch. The damaged barrier function is also connected with the itch-scratch cycle 
and further augments this vicious cycle.
21
 There are several new mediators that have 
been suggested to be involved in AD- induced itch, such as interleukin(IL)-31, serine 
proteases, and nerve growth factor (NGF). This indicates that there are peripheral and 
central mechanisms and mediators implicated in the pathogenesis of itch in patients 
with AD.
21
 
   As stated above AD is a disease known to be worsened by psychological stress 
5,16
 
and itch may be triggered or enhanced by acute or chronic stress. Interestingly, the 
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NC/Nga mouse has been used in stress experiments, and it was shown that water 
avoidance stress could lead to eczema even if the mice were kept in a sterile 
environment.
22
 
 
 
1.3 SEROTONIN 
 
5-HT is a monoamine. It is synthesized from tryptophan, which contains an indole 
ring and a carboxyl-amide side-chain. The rate limiting agent regarding the synthesis 
of 5-HT is tryptophan hydroxylase. 
   5-HT is a signalling molecule distributed broadly throughout the body, acting in the 
central and peripheral nervous system as a neurotransmitter. There are widespread 
serotonergic projections arising from the raphe nuclei in the brainstem, and 5-HT is one 
of the most broadly distributed neurotransmitters within the brain.
23
 In man it is mainly 
found in the periphery, in platelets, while in lower animals also being found in mast 
cells.
24
 The major source of 5-HT is the gut (enterochromaffin cells). 5-HT has 
profound effects both at the central and peripheral levels of the neuroendocrine system.  
It is playing an important role in regulating appetite, learning, behaviour, sexual desire, 
sleep, memory, and stress response.
25
 It is also found in high concentrations at sites of 
inflammation. Platelets will release 5-HT upon aggregation after tissue injury. It is also 
assumed that 5-HT at the cellular or molecular level might influence differentiation, life 
span and dendricity of different cells.
 25-26
 
    In the skin, 5-HT is expressed by melanocytes, Merkel cells and inflammatory cells, 
with a difference depending on the species.
27,28 
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1.3.1 Serotonin receptors 
5-HT, like a few other neurotransmitters, such as acetylcholine, glutamate, and γ-
aminobutyric acid (GABA), acts via two categories of receptors: ionotropic and 
metabotropic receptors. Ionotropic receptors (channel receptors) have a low affinity for 
their neurotransmitter ligand but a rapid activation constant (a few milliseconds). In 
contrast, metabotropic receptors (receptors acting through G protein activation and 
second messenger production) exhibit both a high affinity for their neurotransmitter and 
a slow activation constant (in seconds or longer).
29
  
    The effects of 5-HT are thus mediated by cell surface membrane-bound receptors (R) 
of at least 21 different subtypes. The most well-characterized are the 5-HT1A and 5-
HT2A receptors.
25
  
  5-HT1AR is a “transiently expressed” intronless receptor, that is, at specific times in 
development of/or during stress, quickly expressed at very high amounts. Decrease in 
5-HT1AR number is probably due to increased 5-HT brain levels, since the 5-HT1AR 
expression is sensitive to autoinhibition. 
   The 5-HT1AR and 5-HT2AR have opposing functions in a variety of cellular and 
behavioral processes. The 5-HT1AR develops early in the central nervous system 
(CNS) and is associated with reduction of c-AMP levels in neurons. These actions 
provide intracellular stability for the cytoskeleton and result in cell differentiation and 
cessation of proliferation.  Clinically, 5-HT1AR drugs decrease brain activity and act as 
anxiolytics. The 5-HT2AR develops more slowly and is associated with increased Ca 
++
 
availability in neurons. These actions destabilize the internal cytoskeleton and result in 
cell proliferation, synaptogenesis, and apoptosis. In humans, 5-HT2AR drugs produce 
hallucinations.
25
 
   Both these 5-HT  receptors are involved in anxiety and stress.
30,31
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1.3.2 Serotonin transporter protein  
The serotonin transporter protein (SERT; 5-HTT) belongs to the family of monoamine 
transporters and serves the high affinity reuptake of 5-HT into presynaptic terminals. 
SERT thus reuptakes, but may also release, 5-HT and therefore determines the 
magnitude and duration of the serotonergic response. Serotonin reuptake inhibitors 
(SSRIs), used for treating mood disorders, are acting by inhibiting the reuptake of 5-HT 
by SERT. Therefore, SERT has effectively been established as the initial target for 
clinically useful anxiolytic and antidepressant drugs.
23
 
   Genetic variations in promoter and intron regions of the SERT-gene are seen in 
individuals more prone to stress and depression.
32,33
 An increase of epidermal and 
dermal cells expressing SERT, being dendritic or round mononuclear, in involved 
compared to non-involved inflammatory skin, have been observed in previous 
studies.
34
  
 
1.3.3 Serotonin and inflammation 
 
During inflammation the 5-HT expression in the skin is limited to platelets. 5-HT 
during inflammation activates receptors, such as 5-HT1AR and 5-HT2AR. Regarding 
5-HT1AR, 5-HT endorses inflammation by way of increasing the number of mast cells 
at the site of the injury via this receptor. The human mast cells contain and releases 5-
HT, which has been demonstrated to contribute to allergic inflammation in mice.
35
 
    5-HT in the skin has proinflammatory, vasodilatory and pruritogenic effects.
36, 37
 
    Agonists to 5-HT1AR, buspirone, and spiperone 
37
 were able to suppress allergic 
contact eczema,
38
 while an antagonist to a 5-HT2AR, ketanserine, also suppressed 
allergic contact eczema.
39
 SERT is involved in inflammation via different neuronal and 
non-neuronal pathways.
40
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1.3.4 Serotonin in atopic dermatitis 
 
It has been reported that 5-HT plasma levels were elevated in AD patients compared 
with a healthy control group, and this elevation was correlated with the extent of the 
disease.
41
 In addition, a 5-HT1A agonist, tandospirone, has been shown to improve the 
clinical features of AD.
42,43
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2 AIMS 
 
To investigate the role of 5-HT in a mouse model of atopic eczema, which is subjected 
to chronic mild stress, via studying the expression of serotonergic markers, 5-HT, 5-
HT1A and 5-HT2A receptors and SERT,  in the skin, cerebrum and cerebellum (I and 
II).  
 
To study the expression of these serotonergic markers in the skin of human AD patients 
and to correlate clinical, laboratory and psychodemographic data, focusing at chronic 
stress, anxiety and depression (III). 
 
To investigate 5-HT as a pruritogenic and vascular affecting substance in the skin of   
AD patients compared to healthy controls (IV). 
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3 MATERIALS AND METHODS 
3.1 ANIMAL STUDIES (I AND II) 
In total, 24 6-week-old female NC/Nga mice (Charles River Laboratories, Germany) 
were used. The experiments were approved by the local Animal Ethics Committee. 
Animals were left to acclimatize for 1 week prior to the experiments after delivery from 
the vendor.  
 
Chronic stress and immunization 
 
The chronic mild stress procedure used has been described by Lanfumey et al.
44
 and  
was used in a previous study.
45
  
   Briefly, mice were kept in a Scantainer box type 50-SCNT-Z11 (Scanbur AS, Köge, 
Denmark), in a conventional facility, and fed with pellets (R70, Granngården, Malmö, 
Sweden) and tap water. Different stressors were used on weekly basis, such as reversed 
light/dark cycle, one period of confinement to small cages for 12 h, two periods of 
placement with foreign mice for 2 h, one period of continuous overnight illumination, 
one overnight period of wet soil, one period of cage-tilting (30°) for 12 h and one 
period, 3 h, of food and water deprivation. Mice were divided into three groups (eight 
mice per group). One group was stressed and sensitized (stressed eczematous, SE). The 
mice in this group were subjected to chronic mild stress for 12 weeks, and eczema was 
induced from week 9, by painting their ears with a mite antigen, Dermatophagoides 
pteronyssinus (Allergon, Ängelholm, Sweden), at a concentration of 10 mg/ml, which 
had been dissolved in phosphate-buffered saline (PBS) and 0.5% Tween 20. A non-
sensitized control group was similarly stressed (stressed control, SC), and had their ears 
painted using the solvent. A second sensitized group was relieved from stress (non-
stressed eczematous, NSE), being kept in a regular cage and the mice in this group 
were also painted on their ears with the mite antigen from week 9. These mice were 
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maintained on a 12 h light/dark cycle under controlled temperature between 18 and 
22°C and a humidity of 40-60%. 
 
Processing of samples 
 
 After 12 weeks, the animals were killed by cervical dislocation and the ear thickness 
was immediately measured using a calliper (Kroeplin, Schluchtern, Germany), before 
being preserved together with the cerebri and cerebelli, for further analysis. Plasma 
corticosterone was measured using a corticosterone RIA kit (RS 490 11) from IBL 
(Hamburg, Germany) following the instructions of the manufacturer. 
     Tissue samples from the ears, cerebrums and cerebelli were subjected to 
immunohistochemistry in order to analyze changes in the serotonergic markers. For this 
purpose, the samples were fixed in Lana´s fixative (phosphate buffered 4% 
formaldehyde containing 0.2% picric acid) for 2 h at 4°C. They were then rinsed with 
0.1 mol/L phosphate buffer containing 10% sucrose for at least 24 h. Tissues were then 
embedded in Tissue-Tek OCT Compound (Sakura Finetek, Zoeterwoude, The 
Netherlands) and sectioned (14 m thick) using a Microm cryostat (Heidelberg, 
Germany). Cryosections were then mounted on Super Frost Plus glass slides (Menzel-
Gläser, Freiburg, Germany) and stored at -70°C until being used for 
immunohistochemistry employing an immunofluorescence technique. 
  
Immunohistochemistry 
A biotinylated-streptavidine technique was used to detect all antibody-labelled 
molecules. The primary antibodies used overnight at 4
o
C, were rabbit polyclonal rabbit 
antibodies against 5-HT (20080; dilution 1:10,000; DiaSorin, Stillwater, MN, USA), 5-
HT2AR (24288; 1:300; ImmunoStar, Hudson, WI, USA) and SERT (SERT#48; 
1:2,000),
46,47
 as well as a polyclonal guinea pig antibody against 5-HT1AR (AB5406; 
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1:7,500; Chemicon, Temecula, CA, USA). Slides were then incubated with secondary 
biotinylated anti-rabbit (BA-1000) or anti-guinea pig (BA- 7000) antibodies (1:2,000; 
Vector, Burlingame, CA, USA) for 40 min at room temperature, and finally the 
fluorochrome Cy2-labelled streptavidin (PA42001; 1:2,000; Amersham Pharmacia 
Biotech, Uppsala, Sweden) was added for 40 min at room temperature for visualization 
of antibody target labelling. When staining for 5-HT, adjacent sections were also 
stained with a rabbit polyclonal antibody against tryptase (1:20,000), a kind gift from 
prof. I. Harvima, Kuopio, Finland. We also performed double staining in order to 
confirm the neuronal characteristics of the 5-HT2AR- and SERT-positive nerve-like 
bundles. For this purpose we used a guinea pig polyclonal antibody against protein 
gene product 9.5 (PGP 9.5) (GP14104), at a dilution of 1:1,000 (Neuromics, 
Minneapolis, MN, USA), the secondary biotinylated anti-guinea pig antibody (from 
above) and then streptavidine-conjugated Texas Red (SA-5006; 1:2,000; Vector). All 
antibody solutions were diluted in PBS containing 1% bovine serum albumin (BSA) 
(A9418, Sigma-Aldrich, Stockholm, Sweden) prior to use. 
   As controls, the primary antibodies were omitted or normal rabbit serum IgG (X 936, 
Dako, Glostrup, Denmark), or guinea pig serum IgG (006-000-003; Jackson Immuno- 
Research, West Grove, PA, USA) were used at the same dilution as the primary 
antibodies. In addition, we performed preadsorption for 5-HT (serotonin creatine 
sulfate monohydrate, 85030; Sigma-Aldrich, Stockholm, Sweden), 5-HT1AR (AG349, 
Chemicon), 5-HT2AR (24333, Immunostar) and SERT (K596 peptide- the target for 
the SERT antisera). In the case of 5-HT, we utilized serotonin creatine sulfate at a 
concentration of 10
-3
 mol/L, the 5-HT1AR and 5-HT2AR peptides were used at a 
concentration of 5 µg/ml, respectively, whereas the SERT peptide was used at 1 µM. 
All the above mentioned controls resulted in substantially decreased or abolished 
   15 
signals. Finally, the sections were mounted with Kaiser’s glycerol gelatine (Merck, 
Darmstadt, Germany) before being covered with glass slips. 
 
Microscopy  
 
Labelled skin sections were analyzed using a fluorescence Zeiss Axioskop 2 MOT 
microscope (Carl Zeiss, Stockholm, Sweden). The numbers of 5-HT-positive 
mononuclear cells were counted in four representative wells per ear section of the skin 
and the mean was calculated. Epidermal area of expression was estimated as: 0–25% 
(1), 26–50% (2), and higher than 50% (3). Fluorescence intensity was scored as: none = 
0, low = 1, moderate = 2 and high = 3. The number of immunoreactive nerve bundles 
were calculated per section, the absolute number being given, and the intensity of 
staining being semiquantitatively evaluated as none = 0, low= 1, moderate = 2 and high 
= 3.  
     For the cerebrum, a semiquantitative technique was used. The cells in the prefrontal 
cortex immunoreactive for the different markers were evaluated as: none = 0, low = 1, 
moderate = 2 and high = 3, and their intensity as above. In the hippocampus, we 
focused on CA1 and CA3 regions and used 1 = 1–3, 2 = 4–6 and 3 = 7 or more positive 
cells in the respective area. The intensity was scored as above.  
     In the cerebellar study, for the 5-HT1AR, an image analysis technique was used 
with an appropriate software (Easy Image Analysis, Bergström Instruments, Solna, 
Sweden). Labelled sections were examined using the fluorescence microscope. Images 
of 4-6 sections were captured by a digital camera connected to a PC before being 
analyzed using the software. The area fraction (ratio of specifically immunoreactive/ 
nonimmunoreactive areas) was calculated. 
   For the 5-HT2AR a semiquantitative technique was used, focusing at the density of- 
the Purkinje cells, being absent=0, low=1, medium=2 and high=3, and the  intensity of 
the staining signal, none=0, low=1, moderate =2 and high =3. Slides were coded prior 
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to analysis to permit blind evaluation. Also here four to six microscopic fields per 
section were selected and used for quantification. 
 
3.2 HUMAN STUDIES 
 
3.2.1 Immunohistochemical-correlative study (III) 
 
Patients 
 
Twenty eight patients, 18 females and 10 males, with a mean age of 29.5 years (range 
19-48 years) were recruited. They had ongoing AD, according to the criteria of 
Williams et al.
3
 and itching ( in the past 3 days), and had been referred by their family 
doctors to The Department of Dermatology. The patients should not have had systemic 
therapy (including phototherapy and antihistamines) within one month before the study.  
   Ten healthy control individuals, mainly staff and students, 5 males and 5 females 
(mean age 37.7 years (range 20–61 years)), with no history of atopic manifestations for 
themselves, previous and present hay fever, asthma nor AD, were also recruited.  
    Ethical permission was obtained from the local ethical board. 
 
SCORAD  
 
Extent of the disease was determined using SCORing of Atopic Dermatitis 
(SCORAD).
48
 Both objective and subjective SCORAD were determined. 
 
Clinical pruritus 
The degree of clinical pruritus was determined using a visual analogue scale (VAS). 
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Chronic stress 
 
Degree of chronic stress was measured by the salivary cortisol test.
49
 Samples were 
obtained from 20 patients. Salivary cortisol was measured in the morning of three 
consecutive days. In the evening of day 3, 0.5 mg dexametasone was administered 
orally, thereby blocking input from hypothalamus on adrenal cortex, followed by a new 
salivary cortisol test on the fourth day. A ratio between the mean value of the first three 
days and day 4 was calculated, where a ratio below 2 is an indicator of chronic stress. 
Immunoassay was done at the Sahlgrenska University Hospital, Gothenburg, using a 
radioimmunoassay (RIA) method. 
 
 
Psychodemographic data 
 
The patients personality traits were evaluated by using the SSP (Swedish Universities 
Scales of Personality),
50
 a 91 item questionnaire, filled by the patients and analyzed 
regarding somatic trait anxiety (STA), psychic trait anxiety (PsTA), and stress 
susceptibility (SS). Instructions on how to fill in the forms were given by the physician. 
To assess depression MADRS-S (Montgomery-Åsberg Depression Rating Scale-Self 
assessment) 
51
 was used. 
 
 
Processing of biopsy specimens 
 
Biopsies, 3 mm, were taken from L (lesional) skin (with dryness, paples, often 
lichenified) of the elbow, and N-L (non-lesional) skin from the lower back region. No 
topical steroids had been used on any of the areas for at least 14 days. Lana´s fixative 
was used for fixation of the biopsies for 2 h at 4
o
C. After fixation they were rinsed in 
0.1 M Sörensen’s phosphate buffer supplemented with 10 % sucrose for at least 24 h 
and then rapidly frozen and stored at -70°C until further processing. While still frozen, 
the biopsy material was placed in a tissue holder, embedded in Tissue-Tek OCT 
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Compound. A Microm HM 500 cryostat was used for cutting the biopsies into 14-µm 
thick sections and mounted onto Super Frost glass slides for immunohistochemical 
staining using a biotinylated-streptavidine procedure.   
 
Immunohistochemistry 
Sections prepared as described above were incubated first with 10% normal goat serum 
(S 100, Vector, Burlinghame, CA, USA) for 40 min and were then incubated overnight 
at 4
o
C with  rabbit polyclonal antibodies against 5-HT (20080, dilution 1:10,000; 
Diasorin, Millwater, USA) or  5-HT1AR (SlA-170; used at a dilution of 1:1,000). The 
5-HT1AR antibody is directed against amino acids 170–186 in the second extracellular 
loop.
52
 Alternatively, the sections were incubated with 10% normal horse serum (S-
2000, Vector) followed by mouse monoclonal antibodies toward SERT(ST51-5, diluted 
1:10,000, MabTechnologies, Stone Mountain, GA, USA) directed against amino acid 
residues 51-66 coupled to keyhole limpet hemocyanin (KLH) through an additional N-
terminal cysteine residue or  5-HT2AR (sc-166775, dilution 1:400; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). Thereafter, incubation with streptavidine-
biotin-labeled anti-rabbit (BA-1000) or anti-mouse (BA-2000) IgG (both in dilution 
1:200; Vector) as the secondary antibodies was performed for 40 min at room 
temperature, followed by treatment with the fluorochrome Cy2-labelled streptavidine 
(PA42001, 1:2,000; Amersham Biosciences) for 40 min at room temperature.  
   Control staining with unspecific mouse IgG of the same isotype (X0931, Dako, 
Glostrup, Denmark) and in the same dilution as the monoclonal antibody against 
SERT or 5-HT2AR, was negative. In the case of polyclonal antibody toward 5-HT, 
preadsorption with this compound (85030, Fluka, Sigma-Aldrich), at a concentration 
of 10
-6
 mol/L, eliminated the immunostaining. Moreover, when the primary 
antibodies were omitted, a substantial reduction or no staining occurred.  
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Microscopy 
Of general histopathological changes, hyperkeratosis, acanthosis and degree of 
infiltration by inflammatory cells in the dermis were graded semiquantitatively, 0-3 
(0= normal appearance, 1= mild, 2= moderate and 3= severe).  
   The degree of 5-HT-IR was determined in the epidermis and inflammatory 
infiltrates, graded 0-3, and the absolute number of 5-HT-positive platelets were 
determined.  
    For 5-HT1AR the fraction of positive staining in the epidermis was evaluated, 
0=0%, 1=25%, 2=50% and 3=75%. The absolute number of positive 5-HT1AR 
inflammatory cells in the papillary dermis was determined.  
    For 5-HT2AR the epidermal fraction expressing 5-HT2AR of the total thickness of 
epidermis was, similarly as the 5-HT1A epidermal fraction, graded 0-3. The basal 
membrane intensity was graded 0 for minimal staining, and 1-3 for increased staining 
intensity. The number of vessels expressing 5-HT2AR in papillary dermis was graded 
0-3 (0<40, 1=40-60, 2=60-80 and 3=80 vessels per section). 
   The number of SERT-positive mononuclear cells was counted in the epidermis and 
papillary dermis, respectively. In addition, the immunoreactivity was determined in 
the basal epidermal layer and the signal intensity assessed 0-3, as absent, weak, 
moderate or strong. 
 
3.2.2 Intradermal injection study (IV) 
 
 
Subjects 
 
Twenty five patients, 14 females and 11 males, with a mean age of 31.1 ± 7.8 years 
(range 19-46 years), with ongoing AD and itching (in the past 3 days and with a wide 
individual itch range), were recruited. They had been referred by their family doctors to 
The Department of Dermatology.  
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   The patients were diagnosed as having AD using the criteria of  Williams et al.
3 
The 
scoring of AD (objective SCORAD) was 32.8 ± 12.3, the clinical itch for the previous 
three days according to VAS was 3.9 ± 2.1cm, and a Patient-Oriented Eczema Measure 
(POEM) 
48
 was 12.1 ± 6.3.  
   The patients should not have had systemic therapy (including phototherapy and 
antihistamines) within one month before the study. They were allowed to use topical 
therapy (glucocorticoids, calcineurin inhibitors) on L skin of the arm to be injected, but 
not on N-L skin (the site of injection). 
    Twenty five healthy control individuals, mainly staff and students, 17 females and 8 
males, mean age 30.4 ± 6.2 years (range 22-41 years), with no history of previous or 
present hay fever, asthma or AD/eczema, were also recruited. 
    The experiment was run during the time period of March until May 2011. Ethical 
permission was obtained from the local ethical board.  
 
 
Substances 
 
All substances were dissolved in sterile, pyrogen-free, physiological saline containing 
10% (v/v) Sörensen phosphate buffer (Na2 HPO4 + KH2 PO4 67 mmol/L; pH 7.4). 5-
HT was used at a concentration of 2.5 mg/ml, chosen after a pilot study.  Histamine 
dihydrochloride 10 µg /ml (Sigma-Aldrich, Sweden) was used as a positive control and 
Sörensen’s buffered saline as a negative control. The histamine dosage is one of the 
standard dosages that we, as well as others, have used in studies of experimental itch 
with histamine, see, e.g.,
53-66
. The substances were injected intradermally and 
separately in random order in volumes of 20 µl. Injections were given into N-L areas, 
with no visible or palpable lesion within a 5 cm area, on the lateral part of the upper 
arms of the subjects. No injections were given into L areas, because of difficulties to 
standardize such lesions and to measure vascular effects. 
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The substances had been coded in vials with different colours by a lab technician. 
Decoding was done after the completion of the whole study. Thus, the experiment was 
carried out under double-blind conditions. To maintain experimental consistency, the 
same individual performed the experiment, including the injections and supervision of 
the recordings in all subjects. 
 
Recordings of experimental pruritus 
Both the duration and intensity of pruritus were recorded simultaneously with the VAS 
attached to a computer (Somedic, Hörby, Sweden), whereas the areas of the flare and 
wheal reactions were measured with a ruler after each injection. The subjects were 
asked to rate their itch by moving a knob on a 100-mm VAS, which was graded from 
‘no itch’ (0 mm) to ‘maximum itch’ (100 mm). All subjects were instructed to 
continuously adjust the position of the knob so that the position should always reflect 
the present itch. The investigator also regularly reminded the subjects about this during 
the experiment. The subjects always used their dominant hand to ensure the best 
motoric precision of the rating. In addition, the localization of the different injection 
sites was randomized to avoid a systematic error depending on localization.  
   The time intervals between each injection and the initiation and termination of 
pruritus were recorded. Thus, calculations of itch latency (sec), itch duration (sec), 
maximum itch intensity (mm) and area under the curve (AUC) (mm x sec) were 
automatically downloaded into the computer. Such methods for measuring 
experimental pruritus have been used extensively and were validated in previous 
studies.
54- 56
 The areas of flare and wheal reactions were recorded after 5 min and 
outlined on a transparent plastic film. We considered 5 min as most appropriate based 
on earlier studies 
57,58,69   
and, in addition, a pilot study in the present investigation 
showed rather constant values for the wheal, while the flare was slightly increasing 
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with time (0-15 min). The maximum perpendicular diameters for the flare were 
measured in mm and the surface calculated in square mm,
59
 
 
while in case for the wheal 
the maximum diameter in mm was recorded. The wheal was recorded by measuring 
only one diameter, because pilot tests with the dosages we used showed that the 
reactions were always round or oval and symmetrical with no pseudo-pods, making it 
necessary to measure a perpendicular diameter. The reactions to all injected substances 
were followed for 15 min regardless of having itch or not. 
 
3.3 STATISTICAL ANALYSIS 
 
Study I 
For comparison of the number of 5-HT-positive cells between the groups, Student’s t-
test was used. For the semiquantitative data, the chi-square test and/or Fisher’s exact 
test were used. A p value of <0.05 was regarded as significant (also being the case for 
the following studies). 
 
 
Study II 
 
Multiple comparisons of continuous data were performed by analysis of variance, 
ANOVA. In the case of a statistically significant result in the ANOVA, statistical 
comparisons between two arbitrary groups were made by use of the post-hoc test 
proposed by Fisher to control for multiplicity.
19,60
 
 
 
 
 
 
Study III 
 
Processing of the absolute numerical data was done to find out if there was any 
difference between L and N-L skin, and normal healthy skin (non-parametric test). For 
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the semiquantitative data, the chi-square test and/or Fisher’s exact test were used in 
non-dependant samples, and Student´s t-test or non-parametric test, if dependent 
samples. Correlation between the different parameters was measured using Spearman´s 
or Pearson’s tests.  
 
 
Study IV 
 
Student´s t-test, and the Wilcoxon signed-rank test for dependant samples and the 
Mann-Whitney test for independent samples were used. The Spearman´s rank-order test 
was used to determine the correlation between the variables.  
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4 RESULTS 
4.1 ANIMAL STUDIES (I AND II) 
 
General findings 
The diameter of the ears was larger in the SE group, 0.49 ± 0.11 (mean ± SD) mm, 
compared to the NSE group, 0.36 ± 0.13 (p < 0.01) and the SC group, 0.23 ± 0.00 (p 
< 0.001). 
 
Corticosterone levels 
The SE group showed lower (p < 0.05) corticosterone values 496.4 ± 221.5 ng/ml, 
compared to the other groups, 738.6 ± 232.1 in the NSE and 805.2 ± 144.4 ng/ml in 
the SC. 
 
Skin 
There was an increase (p < 0.01) in the number of 5-HT-containing dermal mono-
nuclear cells in the mice with induced eczema (SE 295 ± 46 cells/section and NSE 
259 ± 58) compared with the control group (SC 164 ± 23). There was a trend (p = 
0.09) toward more 5-HT-containing cells in the SE group, compared with the NSE. In 
the SC group, the 5-HT-positive cells were smaller and less granulated, whereas in 
the SE group, they were larger, often degranulating, widely distributed and located 
closer to the epithelium compared to both the NSE and SC groups. When staining 
adjacent sections for tryptase a similar expression was obtained indicating that these 
5-HT-positive cells are mast cells. 
   5-HT1AR-IR was seen in the skin sections, with an increase in the eczematous 
groups (p < 0.01 for SE and p < 0.05 for NSE) compared to the control, and with no 
difference between the SE and NSE groups. 
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5-HT2AR-IR was found in nerves, Langerhans cell-like cells and in the apical 
epithelium. In both eczema groups, the dendrites of the Langerhans cell-like cells 
were longer than in the SC group. The 5-HT2AR epidermal area immunoreactivity 
was most evident in the SE (2.4 ± 0.5) and NSE (2.1 ± 0.4) groups compared to the 
SC (1.3 ± 0.5) group, with a difference (p < 0.01) between the SE and NSE groups, 
and between the SE and SC (p < 0.001) groups, whereas the intensity was highest in 
the SE (2.8 ± 0.4) and NSE (2.6 ± 0.6) groups compared to the SC (1.4 ± 0.5) group. 
A difference in intensity levels was detected (p < 0.05) between the SE and NSE, and 
also between SE and SC (p < 0.001). 5-HT2AR expression was also seen on nerve 
bundles, which was confirmed by double staining with PGP 9.5.  
   The number of 5-HT2AR-positive nerve bundles was decreased (p < 0.01) in the SE 
(6.3 ± 3.1 bundles per section) compared to the NSE (11.3 ± 3.6), and SC (8.8 ± 3.4) 
groups. In addition, the fluorescence intensity of the nerve bundles for 5-HT2AR was 
lower (p < 0.01) in the SE (1.8 ± 0.5) as compared with the NSE (2.6 ± 0.7) and SC 
(2.3 ± 0.4) groups. 
   SERT-IR, in addition to the epidermis, was also found in nerve bundles with a 
decreased number in the SE (5.9 ± 2.4) compared to the NSE (11.9 ± 3.1; p < 0.001) 
and SC (9.5 ± 3.2; p < 0.05) groups. There was no difference in bundle intensity 
between the NSE (2.4 ± 0.6), SE (2.1 ± 0.4) and the SC (2.2 ± 0.6) groups. 
 
Cerebrum 
Prefrontal cortex 
No significant changes between the mouse groups were found. The expression of all 
the serotonergic markers was limited in this area. 
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Hippocampus 
There was no difference in neither 5-HT- nor SERT-IR in CA1 and CA3 areas 
between the groups. 
   There was a hippocampal (CA1 and CA3) expression of 5-HT1AR. There was an 
increase (p < 0.05) in the SE compared to the SC group, however, with no difference 
between the SE and NSE, regarding fluorescence intensity in CA1. In the CA3, a 
higher (p < 0.05) immunoreactive cell number in the eczematous groups compared to 
SC, and an increase (p < 0.05) in fluorescence intensity in the NSE in contrast to SC, 
were obtained. 
    In the CA1 area, we noted an increase in the quantity of cells immunoreactive for 
5-HT2AR in the SE (1.5 ± 0.5) compared to the NSE (1.0 ± 0.0; p < 0.05), and SC 
(1.0 ± 0.0; p < 0.05) groups, whereas the fluorescence intensity was 1.6 ± 0.5 in SE, 
1.1 ± 0.4 in NSE and 1.3 ± 0.5 in SC, with a tendency (p = 0.07) toward an increase 
in SE compared to NSE.  In the CA3 area, no differences could be found between the 
SE and NSE. 
 
Cerebellum 
Expression of 5-HT1AR was seen on the Purkinje cells and also some small 
interneuronal cells in the molecular layer. There was a difference (p < 0.001) in the 5-
HT1AR area fraction between the SE, 0.77 ± 0.24 (mean ± SD) and NSE, 1.56 ± 0.42, 
groups, thus, with a lower value in the SE group. The lowest value was found in the SC 
group, 0.18 ± 0.08, also significantly different (p < 0.001) from the other groups. 
The 5-HT2AR was expressed in the Purkinje cells and sometimes in nerve fibres 
extending far out into the molecular layer. The cell density of the immunoreactive cells 
was highest in the SE, 2.2 ± 0.3, compared to the other groups, NSE, 1.7 ± 0.2 (p = 
   27 
0.001), and SC, 1.3 ± 0.3 (p < 0.001), and there was also a difference (p = 0.05) 
between NSE and SC.  
    The intensity of the fluorescence signal was also highest in the SE group, 1.9 ± 0.2, 
compared to the NSE, 1.6 ± 0.3 (p < 0.05), and SC, 1.5 ± 0.4 (p < 0.01). 
 
4.2 HUMAN STUDIES  
4.2.1 Immunohistochemical-correlative study (III) 
 
Clinical data 
The objective SCORAD was 42.3 ±11.5 (mean ± SD) (range 21.2 to 65.5) and 
subjective SCORAD 51.6 ± 13.4 (range 26.2 to 73.5).  The pruritus, using the VAS 
scale, was 5.2 ± 2.4 (range 0-10).  
 
Cortisol ratio 
The cortisol ratio was 2.6 ± 3
.
0 (range 0.3-14.1).  
 
Psychodemographic data 
STA was 15.1 ± 4.3 (range 8-22), PsTA was 15.2 ± 3.8 (range 9-25), and SS 16.3 ± 4.1 
(range 7-24). The score for MADRS-S was 8.0 ± 6.5 (range 0-24). 
 
General histopathological findings 
The degree of hyperkeratosis was higher in L, 1.9 ± 0.7 compared to N-L, 1.2 ± 0.4 
skin and normal healthy skin, 0.6 ± 0.5, a statistical difference (p < 0.001) between L, 
and NL and control skin, respectively, and also (p = 0.001) between N-L and control 
skin. The degree of acanthosis was 2.1 ± 0.8 in L skin, 0.6 ± 0.8 in N-L and 0.5 ± 0.5 in 
normal healthy skin, with a significant difference (p < 0
.
001) between L, and N-L skin 
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as well as the control skin. The degree of inflammation was 2.4 ± 0.7 in L skin, while it 
was 1.1 ± 0.8 in N-L skin and 0.3 ± 0.5 in normal healthy skin. This difference was 
significant (p < 0.001) between L, and N-L as well as control skin, and there was a 
strong tendency (p = 0.06) for a difference between N-L and control skin. 
5-HT 
The epidermal immunoreactivity for 5-HT was similar, 2.1 ± 0.4 in L and 2.0 ± 0.3 in 
N-L skin, while 2.5 ± 0.5 in normal healthy skin.  There was a statistical difference 
between N-L (p < 0.01) compared to the healthy control skin, and a tendency (p = 0.07) 
to a difference between L and control skin   
  The 5-HT staining of the inflammatory infiltrate was 2.0 ± 0.6 in L and 1.8 ± 0.5 in N-
L skin, while being 2.5 ± 0.5 in normal healthy skin. There was a statistical difference 
between L (p < 0.05) and N-L (p = 0.001) skin, compared to the healthy control skin.   
   The highest number of 5-HT-positive platelets, 5.0 ± 2
.
3, was found in L skin, being 
2.0 ± 0.8 in N-L skin and 1.0 ± 0.7 in normal healthy skin. The difference between L 
and N-L skin was statistically significant (p < 0.001), so was the difference between 
healthy control skin, and L (p < 0.001) and N-L (p < 0.01) skin, respectively.  
 
5-HT1AR 
A 5-HT1AR-positive epidermal fraction was found in the apical part of the epidermis, 
more evident (p < 0.001) in the L, 1.1 ± 0.7, compared to N-L skin, 0.3 ± 0.5, and also 
with a higher signal intensity. The fraction in normal healthy skin was 0.3 ± 0.5, which 
means that there is a difference (p < 0.01) against L skin. 
   There were also dermal inflammatory, mast cell-like, cells that expressed the 5-
HT1AR, their number being higher (p < 0.001) in L, 31.9 ± 10.6, compared to N-L 
skin, 17.5 ± 6.0, also the value in the L skin being higher (p < 0.001) compared to 
normal healthy control skin, 14.4 ± 3.6.  
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5-HT2AR 
There was a significant difference (p < 0.05) in epidermal fraction expressing 5-
HT2AR in L compared to N-L skin, reaching 1.8 ± 0.7 in L and 1.3 ± 1.1 in N-L skin. 
In the normal healthy skin the fraction was 0.6 ± 0.5, which is different (p < 0.001) 
from L skin. There was no difference in the epidermal 5-HT2AR intensity.  
   There was a basement membrane signal being more evident in N-L, 2.3 ± 0.7, and 
healthy control skin, 2.4 ± 0.4, compared to L skin, 1.6 ± 0.6. The difference between L 
skin and N-L skin was significant (p < 0.001) and also significant (p < 0.001) between 
L and normal healthy skin. 
   The number of 5-HT2AR immunoreactive vessels in papillary dermis was increased 
(p < 0.001) from normal control skin, 0.8 ± 0.6, and N-L, 0.8 ± 0.7, respectively, to L 
skin, 2.3 ± 0.8.  
 
 SERT 
 There was a higher number of the epidermal SERT-positive cells, 13.8 ± 5.7 and 20.4 
± 12.0 in N-L and L skin, respectively, normal control skin showing 11.5 ± 2.1. There 
was a statistical difference (p < 0.05) between L skin, and N-L skin and healthy control 
skin, respectively. The dermal SERT-positive cells were 20.3 ± 4.5 and 39.9 ± 9.2 in N-
L and L, respectively, while in normal healthy skin being 16.5 ± 3.2. There was a 
difference (p < 0.001) between L and N-L skin as well as healthy control skin and also 
a difference (p < 0.05) between N-L skin and healthy control skin, indicating a role of 
SERT for antigen presentation. There was a higher immunoreactivity in the basal layer 
of the L, 1.6 ± 0.6, compared to N-L, 0.5 ± 0.5, skin, while in normal healthy skin, 0.4 
± 0.5, which indicates that keratinocyte proliferation might be affected by modulating 
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this protein. There was a difference (p < 0.001) between L and N-L skin, as well as 
between L and normal skin. 
 
 
 
Correlations 
 The degree of subjective itch correlated with STA (r = 0.50; p = 0.01) and SS (r = 
0.44; p < 0.05).  
   In the L skin there was a correlation (r = 0.38; p < 0.05) between the number of 5-
HT1AR-positive inflammatory dermal cells and objective SCORAD. Moreover, a 
correlation (r = 0.39; p = 0.05) between the epidermal 5-HT1AR fraction with the 
MADRS-S score and also a reverse correlation (r = -0.48; p < 0.05) between the 5-
HT2AR-positive vessels and the MADRS-S score, was found. There was a reverse 
correlation (r = -0.42; p < 0.05) for the basal epidermal SERT-IR with the SS and a 
tendency (r = 0.36; p = 0.07) to a reverse correlation with PsTA.  
   In N-L skin the objective SCORAD correlated (r = 0.56; p < 0.01) with the degree of 
acanthosis. There was a correlation (r = 0.53; p < 0.05) between the epidermal fraction 
of 5-HT2AR and the cortisol ratio. In addition, a correlation was found between the 
number of 5-HT2AR-positive vessels in the N-L skin and the objective (r = 0.38; p = 
0.05) and subjective (r = 0.39; p < 0.05) SCORAD, respectively.  
 
4.2.2 Intradermal injection study (IV) 
 
The quality of sensation of the experimentally induced pruritus varied among 
participants. Some described pruritus as burning, others as painful.  
   However, there was no difference between the qualitative descriptions reported by 
patients with AD and by healthy controls, regardless of the substance injected.  
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5-HT, histamine and buffer induced itch in 23, 22 and 14 patients with AD and 21, 23 
and 9 healthy controls, respectively. For the different itch variables there was no 
significant difference between patients with AD and healthy controls. However, itch 
latency differed significantly between the substances, being shorter for 5-HT 
compared with histamine, both in patients with AD (p = 0.001) and in healthy 
controls (p < 0.05).  
   5-HT, histamine and buffer induced flare and wheal in all 25 patients with AD and 
in all 25 healthy controls, respectively. However, flare and wheal differed between 
patients with AD and controls, with lower values in patients with AD for 5-HT (p < 
0.01 and p < 0.05, respectively) as well as for histamine (p < 0.001 and p < 0.01, 
respectively).  
   There was no difference between the sexes for itch, flare or wheal results.  
   There was a correlation between the objective SCORAD and the clinical SCORAD 
pruritus (p < 0.001) and POEM (p < 0.01), respectively. There were no correlations 
between the clinical findings (i.e. clinical SCORAD pruritus, POEM), and the 
recorded experimental itch, nor flare or wheal responses for 5-HT in patients with 
AD. There was, however, a negative correlation (p < 0.05) for histamine, between 
clinical SCORAD pruritus and wheal, as well as between POEM and wheal, in 
patients with AD, i.e. the higher the SCORAD pruritus or POEM score, the smaller 
the wheal. 
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5  DISCUSSION 
5.1 ANIMAL STUDIES (I AND II) 
The highest degree of eczema in these studies was found in the mouse group exposed 
to chronic mild stress. This finding is consistent with other studies showing that 
chronic stress may increase an eczematous reaction.
22,61 ,62
 
   It is interesting that the SE group had the lowest level of corticosterone, while both 
the NSE and SC groups had higher levels. The low level in the SE group indicates a 
chronic HPA axis suppression, when both stress and inflammation are combined. In 
AD  patients, a blunt HPA axis responsiveness to stress has been described, resulting 
in a failure to mount a sufficient cortisol response.
63
 
   We observed a decreased neuronal expression of 5-HT2AR and SERT in the skin of 
the atopic-like mouse strain exposed to chronic mild stress. At the same time, we 
detected an increased hippocampal expression of 5-HT2AR, in the CA1 area of the 
cerebrum. These findings are interesting since the CA1 area has been associated with 
chronic stress.
64,65
 The discrepancy with an increased hippocampal signal for 5-
HT2AR but a decreased skin nerve signal for this marker, in the SE group, might be 
due to a downregulation of this receptor in the peripheral neurons and a central 
upregulation in the hippocampus. In addition, the increased 5-HT2AR expression 
may suggest a lower level of the ligand influenced by both stress and eczema. This 
may in turn be reflected on the activity of the HPA system and the subsequent lower 
levels of corticosterone in the SE mice.  
   It has been recently reported that 5-HT1/5-HT2 receptors may be involved in 
scratching in mice.
66
 Prior electron microscopy studies demonstrated that 5-HT2AR 
receptors are expressed on peripheral sensory axons in the rat skin.
67
 We confirmed 
by immunohistochemistry that the 5-HT2AR also exists on sensory nerve fibres 
extending far out into the mouse epidermis. The 5-HT2AR has also been reported to 
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contribute to mechanical hyperalgesia in a rat model of neuropathic pain.
68
 Both 
nociceptive and A-δ nerve cell bodies are also known to express 5-HT2AR in rat 
dorsal root ganglia.
69
 
   We also detected an increase of 5-HT2AR-IR in the ear epithelium of the SE 
compared to the NSE and SC mice. The chronic mild stress appears to have resulted 
in a worsening of the inflammatory status of the skin exposed to the mite antigen, and 
also induced a stronger scratching behavior. The explanation could either be that the 
stress reduced the degree to which the mice were able to cope with the itch stimuli, 
causing a greater scratching behavior. Alternatively, stress responsive pathways in the 
brain may indirectly, via neural or humoral pathways, increase the inflammatory 
response through an impact on inflammatory cells, such as keratinocytes, which have 
been shown to express 5-HT2AR and 5-HT1AR.
70,71
 
   SERT was shown to be present in nerve bundles in the mouse ears, where we 
observed a downregulation in the eczema group exposed to stress compared to non-
stressed eczema group. This is interesting, since SERT modulating effects have been 
suggested to be mediated through the 5-HT2AR.
72
 
   It has been suggested that a 5-HT1AR agonist may be of use in the clinical 
management of stress-associated aggravation of AD in humans.
43
 However, we could 
not find any difference in 5-HT1AR expression between the eczematous groups, SE 
and NSE, neither in the skin nor brain. It was more an upregulation dependent on the 
inflammation, which could be seen in the skin and in the brain.  
   5-HT-containing mast cell-like cells were found to be more numerous in the skin of 
the SE and NSE groups compared to the SC, suggesting that a good part of this effect 
being caused by the eczema per se. However, there was also a tendency for more 5-
HT-positive cells in the SE than in the NSE group suggesting a possible added effect 
of stress. The cells were also larger, more often degranulating and located closer to 
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the basement membrane, consistent with a more vigorous inflammation. In this 
context we note a lack of 5-HT1A receptors on the mast cells, in contrast to findings 
in humans and dogs.
24,70
 The increase in the number of mast cell-like cells and their 
degranulation with secretion of 5-HT in the skin might contribute to a decreased 
peripheral neuronal 5-HT2AR expression.  
   In the cerebellum, chronic mild stress gave a reduced immunoreactivity for the 5-
HT1AR in SE compared to NSE mice, however, the lowest values were found in the 
SC group. This indicates a contribution of the inflammation per se to the increased 
immunoreactivity of this receptor, but at the same time that the stress per se gives a 
decreased immunoreactivity. This reduced immunoreactivity might be due to a 
decreased synthesis of 5-HT1AR, but there are also other possibilities such as  
internalization of the receptor.  
   The 5-HT1AR may be involved in the serotonergic control of growth of 5-HT fibers 
and/or the modulation of Purkinje cell activity 
73,74 
Functionally 5-HT has been shown 
to be able to modify the firing of these cells in the short term by changing the firing 
pattern from regular to burst firing.
74
 This might have an impact on the motor pattern, 
including the scratching behaviour.  In the long term 5-HT may regulate dendrite 
formation in these cells via the 5-HT1AR and 5-HT2AR.
75
 
   Regarding the 5-HT2AR, the highest expression was found in the SE group, while the 
lowest was found in the SC group, indicating a role for the receptor both for the 
inflammation and the chronic stress. These results for the 5-HT2AR are also in line 
with our results from the hippocampus, CA1 area.
76
 Additionally, our results were 
consistent with a recent report about an increase in 5-HT2AR in the cerebellum in a 
model of chronic stress in gold-fish.
77
 
   The functional impact of the modulation of the cerebellar serotonergic receptors 
during chronic mild stress remains to be shown. The Purkinje cells are critical to the 
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output of cerebellum to other brain areas.
60
 In the Purkinje cell layer an expression of 
heat shock protein 70 was shown in an animal model of sustained muscular 
contraction,
78
 suggesting an involvement of these Purkinje cells in muscle tension. AD 
patients may show increased muscular tension,
79
 which may vary depending on the 
degree of anxiety/chronic stress, and here we might be dealing with a possible role for 
the cerebellum and its Purkinje cells.  
   Chronic skin inflammation, as in atopic eczema, may thus affect the function of the 
cerebellum through the serotonergic system. At least two mechanisms might be 
possible- a chemical effect of blood carried inflammatory mediators on the cerebellum-
or an effect of a changed movement pattern. Johansson et al.
80
 showed that skin or 
brain inflammation may have an impact on the cerebellum, confirmed by the increased 
fusion between Purkinje cells in the cerebellum and transplanted bone marrow derived 
stem cells.   
   Since female mice were used in our animal studies we can not rule out the possibility 
of a hormonal impact on the results during the estrous cycle.  
 
5.2 HUMAN STUDIES 
 
5.2.1 Immunohistochemical study (III) 
 
 We found a correlation between itch, which is a primary and critical symptom in AD, 
and SS and PsTA. However, we did not find a correlation between the eczema severity 
(SCORAD) and any psychodemographic data. In addition, it was a rather wide 
deviation regarding the psychodemographic scores. Previously, Oh et al.
7
 reported an 
association of stress with symptoms of AD. Pruritus was correlated with state anxiety 
and trait anxiety, while the SCORAD did not show a correlation with psychological 
parameters. This is to be compared with earlier reports of a special personality in AD 
 36 
being prone to an increased SS.
63
 This also indicates the complexity of this field which 
includes several confounding factors being involved in AD and its worsening.  
   The patients in the study by Oh et al.
7
 included both males and females as was the 
case in our study. This may have an impact on the results. There are gender differences 
regarding anxiety and SS, but we in the present study were primarily interested to study 
serotonergic mechanisms in the different individuals. When extracting the female 
patients we found a correlation between SS and objective SCORAD, which is 
interesting in this respect. Further extended studies, which incorporate gender aspects 
would be of value. 
   Moreover, we did not see a correlation between the cortisol ratios and the severity of 
the disease. The mean cortisol ratio values were in the range of what we define as 
chronic stress. Furuichui et al.
90
 reported increased salivary cortisol levels in AD 
patients in comparison to healthy subjects and that these levels correlated with 
SCORAD values. 
   Furthermore, we did not find a correlation between the extent of the eczema 
(SCORAD) and the pruritus, which contradicts with our earlier findings.
91
 Here we 
might be dealing with confounding factors, such as the climate.  
  There was a difference between N-L and normal healthy control skin regarding 
hyperkeratosis and also a tendency to a difference regarding general inflammation. 
Moreover, there was a correlation between objective SCORAD and the degree of 
acanthosis in N-L skin. These findings are in line with the notion that N-L skin is not to 
be regarded as normal skin. As ´L´ skin we always chose skin from the elbow. This 
skin area is prone to be subjected to scratching. On the other hand most of the lesions of 
AD are dynamic, in contrast to inflammatory lesions of psoriasis. This also supports the 
value of studying N-L skin in AD.  
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A 5-HT1AR- positive signal was found in the apical part of the epidermis, more 
evident in the L compared to N-L skin, which indicates that this receptor has a role for 
keratinocyte differentitation. There were also inflammatory, mast-cell-like cells, which 
expressed the 5-HT1AR, their number being higher in L compared to N-L skin, and 
which may have an impact on the inflammatory process. There was a correlation 
between the number of 5-HT1AR-positive inflammatory dermal cells in the L skin and 
objective SCORAD. In earlier studies on contact eczema 
92 
and psoriasis 
93
 we found a 
lower number of 5-HT1AR-positive dermal cells in L skin. The reason for this 
discrepancy with our findings is not evident, but these inflammatory conditions, with 
the stable psoriasis, and the well defined contact eczematous reaction, are quite 
different from the often scratched AD.  
   Regarding 5-HT2AR, there was a higher epidermal fraction expressing this receptor 
in L compared to N-L skin. In N-L skin there was also a correlation between epidermal 
fraction of 5-HT2AR and the cortisol ratio. This indicates a role for this receptor for the 
keratinocyte proliferation/differentiation and also the importance of chronic stress.  
   The number of 5-HT2AR-positive vessels in the papillary dermis was increased from 
N-L to L skin. The finding of positive vessels might be due to a general importance of 
vessels for the inflammation, but a more specific role of the 5-HT2AR expressed on the 
vessels can not be excluded. There was a correlation between the number of 5-HT2AR- 
positive vessels in the NL skin and the objective and subjective SCORAD, 
respectively.  
   In L skin there was a reverse correlation for the 5-HT2AR immunoreactive vessels 
with the depression score. This might indicate a protective role for this receptor 
regarding depression, which is a somewhat an unexpected finding. However, an anti-
inflammatory effect by this receptor has earlier been reported in rheumatoid arthritis,
94
 
pointing at a complex situation regarding the 5-HT2AR. 
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There were a higher number of the epidermal and dermal SERT-positive cells in the L 
skin compared to N-L skin, indicating a role for SERT in antigen presentation. There 
was also a difference between N-L and control skin regarding the number of dermal 
SERT-positive cells.  
   There was also a higher SERT-IR in the basal epidermal layer of the L compared to 
N-L skin, which indicates that keratinocyte proliferation might be affected by 
modulating this protein. In the L skin there was a reverse correlation for this expression 
with the SS and a tendency to a reverse correlation with PsTA. At the same time a 
correlation was found with the degree of acanthosis and a tendency to a correlation with 
inflammation. This highlights the importance of the SERT both for the inflammatory 
process and possibly a protective effect against SS and PsTA, and suggests that this 
protein might be a target in the future in stress-worsened AD. 
 
5.2.2 Intradermal injection study (Study IV) 
 
There was a similar itch response to 5-HT and to histamine, at the group level, in N-L 
skin of patients with AD and healthy controls. On the other hand, 5-HT, analogous to 
histamine, gave smaller flare and wheal responses in patients with AD compared with 
healthy controls. 
   It is well known that patients with AD have an abnormal vascular response with a 
tendency to vasoconstriction.
95,96
 This may explain the different vascular effects 
induced by 5-HT and histamine in our patients with AD and healthy controls. 
   Hosogi et al.,
58
 using iontophoresis, found a lower itch response to 5-HT in N-L 
compared with L skin of patients with AD, whereas the itch response of healthy 
controls was in the range of the L skin.  
   The means of administration of substances and the locally reached tissue 
concentration might be responsible for different results at the group level in our study 
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and earlier studies. We chose the injection technique rather than iontophoresis, as it 
has the advantage that the dosage can be calculated from the injection volume and 
substance concentration. A concentration of 2.5 mg/ml was used because it gave a 
reliable itch reaction in our pilot study. This corresponds to an absolute dosage of 50 
μg, which is similar to 5-HT doses used by Fjellner and Hägermark.81 We have 
previously found the concentration of 5-HT to be 9.85 ng/g in healthy skin and 24.25 
ng/g in eczematous skin.
97
 Our dosage might not be physiological; however, during 
inflammation high concentrations in local tissue may be achieved.  
   It is not surprising that iontophoretically applied pruritogens induce a more 
pronounced itch response in L skin, with its damaged skin barrier, than in N-L skin. 
The question is whether this reflects only the delivery of a higher dosage through the 
damaged skin or increased sensitivity to these pruritogens in the L skin.     
   There was a difference in sex proportion between patients with AD and healthy 
controls, yet we could not observe a difference between the sexes either for the itch or 
the flare or wheal results. This is in accordance with no difference between men and 
women for itch responses elicited experimentally with histamine, compound 40/80 or 
wool.
55
  
   5-HT also induced pruritus in normal individuals. This is in line with previous 
studies.
81,82 
 The question is how 5-HT causes a pruritic response. A possible 
mechanism is via activation of keratinocytes, e.g., transient receptor potential 
vanilloid (TRPV) receptors,
98
 which, in turn, might activate sensory nerves. Sensory 
nerve fibres may also be triggered, either directly, via 5-HT receptors
36
 or indirectly 
via effect on inflammatory cells, which like keratinocytes, have receptors for 5-HT.
70
 
Another possible mechanism is via an effect on the vessel wall. The fact that the 
pruritic effect did not differ significantly between patients with AD and controls, 
while at the same time, the vascular response did, indicates that the latter is not the 
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primary cause of pruritus. This is supported by a study in which vasoregulation at the 
site of 5-HT injection occurred in the absence of scratching reflexes.
99
  This 
difference between pruritic and vascular effects of 5-HT was studied earlier by 
Yamaguchi et al.
36
 using rodents. In this case it was also stated that the vascular 
response was of less importance in relation to pruritus due to 5-HT. Moreover, the 
lower itch latency for 5-HT compared with histamine might support a direct effect of 
5-HT on itch receptors on sensory nerves. 
   Warmer skin temperatures may evoke itch due to a decrease in threshold for 5-HT-
evoked itch signalling. TRPV4, a warmth-sensitive cation-channel expressed in skin 
cells and sensory neurones, plays an important role in the enhancement of 5-HT-
evoked itch by skin warming.
100
 This may be of particular importance in patients with 
AD, who are sensitive to heat. The room temperature was kept constant for our 
patients with AD and healthy controls, when performing the intradermal injection 
study. 
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6 CONCLUSIONS 
 
AD may be worsened by stress and anxiety. 5-HT is an important mediator in stress 
and anxiety.  In the present study serotonergic mechanisms were studied in AD. 
   In an atopic-like mouse model, NC/Nga, that was subjected to chronic mild stress we 
studied expression of serotonergic markers 5-HT, 5-HT1AR, 5-HT2AR and SERT in 
cerebrum, cerebellum and skin. There was an upregulation of 5-HT1AR in the skin, 
cerebrum and cerebellum, during inflammation, irrespective of stress. The 5-HT2AR 
was upregulated in the cerebrum, hippocampal CA1 area, and in the cerebellum, 
Purkinje cell layer, while being downregulated in the skin, during chronic mild stress.  
   In human AD patients serotonergic markers in relation to extent of the disease, 
pruritus, and psychodemographic data with focus on anxiety traits and depression, 
moreover, levels of chronic stress, were studied. We found a correlation between the 
extent of the disease and dermal 5-HT1AR-positive dermal inflammatory cells in the L 
skin and 5-HT2AR-positive vessels in the N-L skin. There was a correlation between 
depression with the epidermal positive 5-HT1AR fraction, while a reverse correlation 
with the number of 5-HT2AR expressing vessels, both in the L skin. In the L skin there 
was a reverse correlation for the basal epidermal SERT-IR with the SS.  
   Moreover, the effect of intradermal injection of 5-HT was studied in patients with AD 
and in healthy controls, on vascular response and pruritus, estimated by a computerized 
VAS recorder. No difference was seen regarding pruritus, while the vascular response, 
was reduced in the AD patients compared to the healthy controls. This study confirms 
a pruritogenic role of 5-HT, both in patients with AD and in healthy controls, and 
shows a lower vascular response of 5-HT in patients with AD compared with healthy 
controls. In addition, the short itch latency time might indicate a direct effect of 5-HT 
on itch receptors. 
   5-HT seems to have a role in AD.  
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7 FUTURE PERSPECTIVES 
In the present thesis we have studied the expression of serotonergic markers in atopic 
eczema/AD by immunohistochemistry. It is difficult to tell exactly how this expression 
mirrors the synthesis or internalization of, e.g., serotonergic  receptors.  
   It would in this respect be interesting to use confocal microscopy to be able to study 
the localization of the serotonergic markers more in detail. 
   There is a lack of methods in order to study the functionality of the receptors using 
methods such as autoradiography, mainly due to the probably low numbers of receptors 
in the skin and lack of suitable tools such as labelled ligands. We need techniques, 
where we could study both ligands and receptors in the same tissue sections.  
   We need to use more NC/Nga mice in order to study a non-stressed control group. 
Also use male NC/Nga mice to study possible gender differences. The latter is also the 
case for human study, where the patient material should be increased. 
   We have been focusing at trait anxiety in the present thesis. There was a correlation 
between our anxiety parameters and depression. Still it may be of interest to use tools to 
measure the ongoing (state) anxiety in patients with AD, such as Hamilton Anxiety 
Rating Scale (HAM-A) and Hospital Anxiety and Depression Scale (HAD).  
   It should be of interest to extract human AD patients with increased SS and 
investigate such patients with fMRI in order to be able to investigate brain tracts for 
possible future pharmacological treatment of stress worsened AD.  In that respect we 
should focus on the amygdale.  
   We need to perform a clinical treatment study of patients with AD using a 
serotonergic compound, such as an SSRI. We will monitor the extent of the disease, the 
degree of pruritus, chronic stress and psychodemographic data, and quality of life in 
these patients 
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8 SAMMANFATTNING PÅ SVENSKA 
 
Atopisk dermatit (AD) kan förvärras av stress och ångest. Serotonin (5-hydroxitryp-
tamin; 5-HT) är en viktig mediator i stress och ångest. I denna avhandling har 
serotonerga mekanismer studerats vid atopisk dermatit. 
   I en atopisk-liknande musmodell, NC/Nga, som utsatts för kronisk mild stress, 
studerade vi uttryck av serotonerga markörer, serotonin, 5-HT1A och 5-HT2A 
receptorer (R) och serotonintransportör protein (SERT) i hud, cerebrum och 
cerebellum. Det fanns en uppreglering av uttrycket av 5-HT1AR i huden, cerebrum och 
cerebellum, under inflammation, oberoende av stress. Samtidigt uppreglerades 5-
HT2AR uttryck i cerebrum, hippocampala CA1 området, cerebellum, i Purkinje 
cellskiktet, medan nedreglerades i huden, under kronisk mild stress. 
   Hos AD patienter studerades dessa serotonerga markörer i förhållande till 
omfattningen av sjukdomen, klåda, kronisk stress och psykodemografisk data med 
fokus på ångestdrag och depression. Vi fann ett samband mellan utbredningen av 
sjukdomen och 5-HT1AR positiva dermala inflammatoriska celler i lesionell hud 
respektive 5-HT2AR positiva blodkärl i icke lesionell hud. Det fanns en korrelation 
mellan depression och den epidermala 5-HT1AR positiva fraktionen, medan en 
omvänd korrelation med antalet 5-HT2AR uttryckande kärl, i båda fall i den lesionella 
huden. I lesionell hud fanns en omvänd korrelation mellan den basala epidermala SERT 
immunreaktiviteten och stresskänslighet. 
   Dessutom har effekten av intradermal injektion av 5-HT studerats hos patienter med 
AD och friska kontroller, beträffande vaskulärt svar och klåda, med hjälp av en 
datoriserad klådmätningsmetod. Ingen skillnad sågs avseende klåda jämfört med friska 
kontroller, medan det vaskulära svaret på 5-HT var minskat hos AD patienter.  
   Serotonin verkar ha en roll i AD. 
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